Co-Diagnostics (HAM:C970) E10: €-28.97 (As of Mar. 2026)


HAM:C970 Co-Diagnostics Inc HAM:C970
63 GF Score
Price €5.55
GF Value €3.88
! 6 Warning Signs
View Full Analysis

What is Co-Diagnostics E10?

Co-Diagnostics HAM:C970 63 E10 is €-28.97 as of Mar. 2026. GuruFocus rates HAM:C970 with a GF Score™ of 63/100 and a GF Value™ of €3.88. The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Co-Diagnostics's adjusted earnings per share data for the three months ended in Mar. 2026 was €-3.512. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-28.97 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-06-27), Co-Diagnostics's current stock price is €5.55. Co-Diagnostics's E10 for the quarter that ended in Mar. 2026 was €-28.97. Co-Diagnostics's Shiller PE Ratio of today is .


Co-Diagnostics  (HAM:C970) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Co-Diagnostics E10 Related Terms


Co-Diagnostics E10 Historical Data

* Premium members only.

The historical data trend for Co-Diagnostics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Co-Diagnostics E10 Chart

Co-Diagnostics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -10.84

Co-Diagnostics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -6.87 -10.84 -28.97

HAM:C970 vs CTSO, NMTC, RDGL: E10 Comparison

For the Medical Devices subindustry, Co-Diagnostics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Co-Diagnostics Shiller PE Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Co-Diagnostics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Co-Diagnostics's Shiller PE Ratio falls into.


HAM:C970
63GF Score
Co-Diagnostics Inc HAM:C970
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Co-Diagnostics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Co-Diagnostics's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-3.512/330.2130*330.2130
=-3.512

Current CPI (Mar. 2026) = 330.2130.

Co-Diagnostics Quarterly Data

per share eps CPI Adj_EPS
201606 -1.057 241.018 -1.448
201609 -1.076 241.428 -1.472
201612 -1.336 241.432 -1.827
201703 -1.770 243.801 -2.397
201706 -2.042 244.955 -2.753
201709 -8.306 246.819 -11.112
201712 -2.788 246.524 -3.734
201803 -2.676 249.554 -3.541
201806 -2.825 251.989 -3.702
201809 -3.342 252.439 -4.372
201812 -3.955 251.233 -5.198
201903 -2.390 254.202 -3.105
201906 -2.124 256.143 -2.738
201909 -2.724 256.759 -3.503
201912 -2.700 256.974 -3.470
202003 -1.357 258.115 -1.736
202006 13.586 257.797 17.402
202009 13.499 260.280 17.126
202012 11.097 260.474 14.068
202103 6.552 264.877 8.168
202106 8.217 271.696 9.987
202109 9.690 274.310 11.665
202112 6.638 278.802 7.862
202203 9.262 287.504 10.638
202206 -2.270 296.311 -2.530
202209 -1.212 296.808 -1.348
202212 -19.541 296.797 -21.741
202303 -5.604 301.836 -6.131
202306 -8.584 305.109 -9.290
202309 -5.622 307.789 -6.032
202312 -13.755 306.746 -14.807
202403 -8.556 312.332 -9.046
202406 -6.968 314.175 -7.324
202409 -8.650 315.301 -9.059
202412 -10.333 315.605 -10.811
202503 -6.521 319.799 -6.733
202506 -5.982 322.561 -6.124
202509 -4.090 324.800 -4.158
202512 -14.219 324.054 -14.489
202603 -3.512 330.213 -3.512

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €-28.97 mean?
Co-Diagnostics (HAM:C970) has a E10 of €-28.97 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Co-Diagnostics and its competitors.
Is Co-Diagnostics' E10 too high?
Co-Diagnostics' current E10 is €-28.97. Overall, Co-Diagnostics has a GF Score™ of 63/100, reflecting its overall financial health beyond just this single metric.
How does Co-Diagnostics' E10 compare to CTSO and NMTC?
Co-Diagnostics' E10 of €-28.97 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Medical Devices & Instruments company?
A good E10 depends on the Medical Devices & Instruments industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Co-Diagnostics and its competitors. Co-Diagnostics's current E10 is €-28.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Co-Diagnostics stock overvalued right now?
Co-Diagnostics (HAM:C970) has a current E10 of €-28.97. The stock's GF Value™ is €3.88, compared to a current price of €5.55 — trading 43% above its estimated fair value. The current E10 is €-28.97. Co-Diagnostics' overall GF Score™ is 63/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Co-Diagnostics (HAM:C970), the current E10 is €-28.97 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Co-Diagnostics (HAM:C970) Overvalued in 2026?

Based on GuruFocus' analysis, Co-Diagnostics stock appears to be overvalued. The current stock price of €5.55 is trading 43% above its estimated GF Value™ of €3.88.

Key valuation signals for HAM:C970:

  • E10: €-28.97
  • GF Value™: €3.88 vs. price of €5.55 (43% above fair value)
  • GF Score™: 63/100 with 6 warning signs

No single metric tells the full story. See the HAM:C970 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Co-Diagnostics Business Description

Other Exchanges CODX:USA0A50:UK
Address 2401 S. Foothill Drive, Suite D, Salt Lake City, UT, USA, 84109
Co-Diagnostics Inc is a molecular diagnostics company. The company develops, manufactures, licenses, and commercializes reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), including molecular tools for detection of infectious diseases. CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and others. The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.
63GF Score

Get the complete analysis for HAM:C970

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.55
Price
€3.88
GF Value